All In Biotech

Drug Trial Radar · NCT05651022

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 28, 2023

Primary completion

Jun 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Indaptus Therapeutics, IncIndustry
Sponsor type
Industry
Collaborators
Translational Drug Development
First posted
Dec 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.

Conditions

  • Solid Tumor, Adult
  • HCC - Hepatocellular Carcinoma
  • CRC (Colorectal Cancer)
  • Pancreatic Adenocarcinoma
  • NSCLC Non-small Cell Lung Cancer
  • Squamous Cell Cancer of the Head and Neck
  • UC (Urothelial Cancer)
  • MSI-H Cancer

Interventions

  • Decoy20Drug

    Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.

  • TislelizumabDrug

    Tislelizumab is a PD-1 inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects with dose-limiting toxicities (DLTs)Time frame: Through study completion, up to 3 years
  2. Percentage of subjects with Adverse Events (AEs)Time frame: Through completion, up to 3 years
  3. Maximum Tolerated Dose (MTD) of Decoy20Time frame: Up to 2 years
  4. Recommended Phase 2 Dose (RP2D) of Decoy20Time frame: Up to 2.5 years

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of Southern California- Norris Cancer Center

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • The Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University, Siteman Cancer Center

    St Louis, Missouri

  • Atlantic Health System

    Morristown, New Jersey

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Gabrail Cancer & Research Center

    Canton, Ohio

  • UH Seidman Cancer Center

    Cleveland, Ohio

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Prisma Health Cancer Institute-ITOR

    Greenville, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.